Pharmaceutical Industry Articles & Reports - Page 15

Analyze 2026 pharma KPI benchmarks. Learn industry median targets for manufacturing OEE, batch release cycle times, deviation rates, and R&D productivity.

Review Teva's $700M acquisition of Emalex Biosciences. Explore how ecopipam, a dopamine D1 antagonist, advances pediatric Tourette syndrome and CNS therapies.

Review how Microsoft Teams, SharePoint, Box, Egnyte, Slack, and Veeva Vault handle FDA 21 CFR Part 11 compliance and GxP document control in life sciences.

Analyze Sun Pharma's $11.75B acquisition of Organon. This report examines deal mechanics, the women's health portfolio integration, and biosimilars strategy.

Compare top 2026 pharma real-world data (RWD) platforms like IQVIA, Komodo, and Truveta. Review pricing models, analytic features, and use-case applications.

A complete guide to pharmaceutical Computer System Validation (CSV) services. Reviews GxP RFP templates, vendor scorecards, and 2026 pricing benchmarks.

Analyze AstraZeneca's acquisition of Modella AI. Learn how multimodal foundation models integrate into oncology drug discovery and impact pharma AI M&A trends.

Analyze Tempus AI's Q1 2026 nine-figure real-world data (RWD) and AI modeling agreements with Merck and Gilead to understand the evolution of RWD pricing.

Analyze the HOPE-3 Phase 3 trial results for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. Review PUL v2.0 data and FDA status.

Review the 2026 FDA approval of vepdegestrant (Veppanu), the first PROTAC targeted protein degrader for ESR1-mutated breast cancer, and its clinical data.

Analyze IQVIA's deployment of 192 pharma AI agents across 64 use cases. Learn how top life sciences CIOs benchmark enterprise AI adoption and ROI in 2026.

Analyze the rise of direct-to-patient pharma platforms. Learn how DTP models integrate telehealth, bypass PBMs, and disrupt traditional pharmacy supply chains.

Analyze Eli Lilly's 2026 AI partnership map and co-innovation strategy. Learn how collaborations with NVIDIA, Insilico, and Chai advance drug discovery.

Review 2026 GLP-1 market access metrics, including PBM prior authorization denial rates, turnaround times, and first-fill benchmarks for commercial teams.

Analyze the FDA AI early-phase clinical trials RFI. This guide covers pilot program objectives, AI evaluation metrics, and evidence-based response strategies.

Examine Phase 2/3 trial results for TAK-881, a 20% SCIG therapy for primary immunodeficiency offering comparable IgG exposure in half the infusion volume.

Comprehensive guide to GxP environmental monitoring systems (EMS) for small biotech. Review FDA 21 CFR Part 11, EU GMP Annex 1, and vendor selection criteria.

An analysis of the May 2026 FDA label expansion for Vyvgart (efgartigimod) in generalized myasthenia gravis, covering triple seronegative subtypes and markets.

Analyze the BeOne-Huahui licensing agreement for the HH160 PD-1/CTLA-4/VEGF trispecific antibody. Review recent China biotech cross-border licensing trends.

Examine BioNTech's 2026 restructuring toward oncology amid declining COVID-19 vaccine revenues, and explore post-pandemic Big Pharma pipeline strategies.

Examine Merck's 2026 restructuring and 8% workforce reduction. Understand how the company utilizes AI and M&A to navigate the $300B pharma patent cliff.

Compare leading AI HCP engagement platforms for pharma commercial operations. Review the 2026 capabilities of Aktana, OptimizeRx, Pega, and Veeva Vault CRM.

Analyze how AI clinical trial recruitment addresses enrollment bottlenecks. This report examines Iterative Health's $77M expansion into cardiology and obesity.

Examine the $2.25B Eli Lilly-Profluent deal. Learn how generative AI and protein design are creating novel recombinases for kilobase-scale genome editing.